StockNews.com Initiates Coverage on Ampio Pharmaceuticals (NYSE:AMPE)

Equities research analysts at StockNews.com started coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Ampio Pharmaceuticals Price Performance

Shares of Ampio Pharmaceuticals stock opened at $0.10 on Tuesday. Ampio Pharmaceuticals has a 52-week low of $0.07 and a 52-week high of $8.30. The company has a 50 day moving average of $0.20 and a 200 day moving average of $1.07. The company has a market capitalization of $113,500.00, a P/E ratio of -0.01 and a beta of 2.21.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.